Pharmaceutical prices go up, up, and awayPosted: October 14, 2009
A Credit Suisse report says leading drugmakers aggressively raised their prices during the third quarter of 2009. I can’t locate the report, but Ed Silverman at Pharmalot helpfully provides the details:
Who led the pack? Schering-Plough (soon to be bought by Merck) with a 12.8 percent hike, while Abbott imposed a 4.4 increase (Abbott’s price hikes have, in fact, been declining over the past year, the report notes). What about the others? Merck upped the ante by 9.9 percent; Wyeth (soon to be part of Pfizer) drove prices higher by 9.3 percent; Lilly was at 9.1 percent; Bristol-Myers Squibb prices rose 8.9 percent; Johnson & Johnson increased prices by 7.8 percent, and Pfizer prices rose 7 percent.